Prostate cancer: an evolving paradigm.

Thumbnail Image
View / Download120.38 KB

Date

2010-05

Authors

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

674
views
403
downloads

Citation Stats

Abstract

Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.

Type

Journal article

Department

Description

Provenance

Subjects

Biomarkers, Tumor, Humans, Male, Neoplasm Staging, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Risk Factors

Citation

Permalink

https://hdl.handle.net/10161/3242

Published Version (Please cite this version)

10.1089/end.2009.0539

Publication Info

Caso, Jorge R, Vladimir Mouraviev, Matvey Tsivian, Thomas J Polascik and Judd W Moul (2010). Prostate cancer: an evolving paradigm. J Endourol, 24(5). pp. 805–809. 10.1089/end.2009.0539 Retrieved from https://hdl.handle.net/10161/3242.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Collections

Scholarly Articles
Full item page

Scholars@Duke

Moul

Judd Wendell Moul

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.